SCM
PFE icon

Silverarc Capital Management’s Pfizer PFE Stock Holding History

Silverarc Capital Management’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-419,134
Closed -$10.4M – 85
2025
Q4 		$10.4M Buy
+419,134
New +$10.6M 1.45% 23
2025
Q3 		– Sell
-344,338
Closed -$8.35M – 92
2025
Q2 		$8.35M Buy
+344,338
New +$8.03M 1.54% 21

Other funds holding PFE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
State Farm Mutual Automobile Insurance
State Farm Mutual Automobile Insurance Bloomington, Illinois $146B AUM 55.73% 1-Year Est. Return

Silverarc Capital Management's PFE Position: Q1 2026 in Review

Silverarc Capital Management sold out of Pfizer (PFE) in Q1 2026, closing a stake of 419,134 shares — an estimated $10.4M sold.

Silverarc Capital Management first reported a position in PFE in Q2 2025 and held it in 2 quarters. The position peaked at $10.4M in Q4 2025. 2,956 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Silverarc Capital Management reported no remaining Pfizer position as of Q1 2026 after selling out during the quarter.
  • Silverarc Capital Management sold 419,134 Pfizer shares in Q1 2026, an estimated $10.4M.
  • Silverarc Capital Management first reported a position in Pfizer in Q2 2025 and held it in 2 quarters.
  • Silverarc Capital Management's Pfizer position peaked at $10.4M in Q4 2025.
  • 2,956 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Silverarc Capital Management's 13F filing for Q1 2026, filed 14 May 2026.